Joint Venture Agreement

Carclo plc
09 March 2007



For Immediate Release                                               9 March 2007

                                   Carclo PLC

                    JOINT INVESTMENT IN PLATFORM DIAGNOSTICS


Carclo Plc ('Carclo'), the technical plastics specialist announces that it has
signed a joint venture with BBI Holdings Plc ('BBI') to acquire up to 50 percent
of Platform Diagnostics (Platform), a privately owned developer of Point of Care
(POC) diagnostics.

Under the terms of the agreement BBI and Carclo will both initially acquire 2.5
percent of the company for a consideration of £40,000 each. Each company will
then receive an additional 2.5% share of the company upon each further £50,000
worth of investment to a maximum 25% or £500,000. Any future investment will
include all laboratory equipment, materials and labour to support this
development.

Platform Diagnostics was founded in 2002 and has been financed by early stage
venture capital funds. The company's expertise lies in the development of POC 
(Point Of Care) diagnostics across a range of technologies, including its
flagship technology Capillary Agglutination Technology (CAT). CAT provides a
platform for digital, rapid, low cost diagnostic tests suitable for the POC
market and overcomes the quantitative limitations of currently available
techniques.

The investment will focus on two technology platforms that Platform is currently
developing. The first is an Intellectual Property protected capillary platform,
which is beyond 'proof of principle'. The first full development target for this
platform will be BBI's newly acquired D-dimer platform which was recently
acquired from Agenix Ltd. The second focus of the investment is a new patented
format of lateral flow which is in development, with proof of principle expected
shortly.

Carclo's Chief Executive Ian Williamson said:
'We are delighted to be working alongside BBI on the development of Platform's
technology. The CAT platform combined with BBI's newly acquired D-dimer
chemistry is an ideal opportunity to bring to market a new generation of low
cost, rapid diagnostic tests for the Point of Care market.'

BBI's CEO Julian Baines said:
'In Platform's technology we have identified a next generation platform for BBI
which demonstrates our commitment to the future of POC, and our investment
developing a strong and diverse pipeline. Platform's technology is highly
synergistic with BBI's current portfolio, and we look forward to taking the
D-dimer test to a new level through this collaboration with Platform.

'In Carclo we have found a global partner that is enjoying significant growth in
its medical and diagnostics manufacturing businesses. Carclo's expertise in
microfluidics, surface coatings and optics will complement BBI's reagent supply
and sales and marketing network. Working together BBI and Carclo expect to
complete the development of the Platform's technology within the next 12 to 18
months.'

                                    - Ends -

Enquiries:
Carclo plc                                                         01924 268040
Robert Brooksbank, Finance Director

Weber Shandwick Financial                                          020 7067 0700
Richard Hews
James White


Notes to Editors

About Carclo (LSE: CAR)

• Carclo plc is a global supplier of technical plastic components. It is a 
public company whose shares are quoted on the London Stock Exchange.

• 75% of sales are derived from the supply of fine tolerance, injection moulded
plastic components, which are used in medical, automotive, telecom and 
electronics products. This business, Carclo Technical Plastics, operates 
internationally in a fast growing and dynamic market underpinned by rapid 
technological development.

• 25% of sales are derived from the supply of manufactured systems to the 
automotive and aerospace industries.

• Carclo's strategy is to grow rapidly in low cost manufacturing regions and to 
develop new technologies and products to underpin future growth.

About BBI Holdings PLC (LSE: BBI):

BBI specialises in the development and manufacture of non-invasive lateral flow
tests, or In Vitro Diagnostics (IVD). Such tests offer a rapid and cost
effective diagnosis for the Point of Care (POC) market, as they are not
laboratory based and can be used at the bedside/doctor's surgery.

About D-dimer

D-dimer includes two diagnostics to detect fibrin degradation products to 
indicate agglutination of the red blood cells, aiding the diagnosis of deep vein 
thrombosis (DVT), pulmonary embolism (PE), and disseminated intravascular 
coagulation (DIC).




                      This information is provided by RNS
            The company news service from the London Stock Exchange